BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 19225113)

  • 1. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
    Hu J; Liu YF; Wu CF; Xu F; Shen ZX; Zhu YM; Li JM; Tang W; Zhao WL; Wu W; Sun HP; Chen QS; Chen B; Zhou GB; Zelent A; Waxman S; Wang ZY; Chen SJ; Chen Z
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3342-7. PubMed ID: 19225113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
    Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J
    Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
    Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
    Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.
    Long ZJ; Hu Y; Li XD; He Y; Xiao RZ; Fang ZG; Wang DN; Liu JJ; Yan JS; Huang RW; Lin DJ; Liu Q
    PLoS One; 2014; 9(8):e104610. PubMed ID: 25122165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
    Jiao L; Wang SJ; Zhuang JL; Zhao YQ; Zhou DB; Xu Y; Han B; Zhang W; Duan MH; Zou N; Zhu TN; Shen T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):555-8. PubMed ID: 19968069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
    Chen L; Wang J; Hu X; Xu X
    Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
    N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
    Xu SN; Chen JP; Liu JP; Xia Y
    Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
    Ohnishi K
    Int J Clin Oncol; 2007 Oct; 12(5):313-7. PubMed ID: 17929112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
    Grimwade D; Mistry AR; Solomon E; Guidez F
    Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
    Nitto T; Sawaki K
    J Pharmacol Sci; 2014; 126(3):179-85. PubMed ID: 25319615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G; Kopp L; Estey E; Wells RJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)].
    Liu YF; Shen ZX; Chen X; Wang AH; Cao Q; Zhu YM; Chen SJ; Chen Z; Wang ZY
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jan; 24(1):25-7. PubMed ID: 12679006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.
    Zhou J; Zhang Y; Li J; Li X; Hou J; Zhao Y; Liu X; Han X; Hu L; Wang S; Zhao Y; Zhang Y; Fan S; Lv C; Li L; Zhu L
    Blood; 2010 Mar; 115(9):1697-702. PubMed ID: 20029047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survey of outcome in acute promyelocytic leukemia.
    Hu J; Shen Z; Sun H; Wu W; Li X; Sun G; Wang Z
    Chin Med J (Engl); 2000 Feb; 113(2):107-10. PubMed ID: 11775530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
    Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
    Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
    Poiré X; Moser BK; Gallagher RE; Laumann K; Bloomfield CD; Powell BL; Koval G; Gulati K; Holowka N; Larson RA; Tallman MS; Appelbaum FR; Sher D; Willman C; Paietta E; Stock W
    Leuk Lymphoma; 2014 Jul; 55(7):1523-32. PubMed ID: 24160850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
    Niu C; Yan H; Yu T; Sun HP; Liu JX; Li XS; Wu W; Zhang FQ; Chen Y; Zhou L; Li JM; Zeng XY; Yang RR; Yuan MM; Ren MY; Gu FY; Cao Q; Gu BW; Su XY; Chen GQ; Xiong SM; Zhang TD; Waxman S; Wang ZY; Chen Z; Hu J; Shen ZX; Chen SJ
    Blood; 1999 Nov; 94(10):3315-24. PubMed ID: 10552940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.